More Arovella Therapeutics Limited news
Arovella Therapeutics LimitedASX: ALA

Reinstatement to Quotation

Oct 11, 2023 at 10:39 PM EDT · Issued by Arovella Therapeutics Limited

Filed with ASX · Oct 11, 2023 at 10:39 PM EDT

On 6ix: 6ix.com/news/reinstatement-to-quotation-73

Arovella Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Arovella Therapeutics Limited on 6ix

Story so far

  • Suspension from QuotationOct 11, 2023
  • Application for quotation of securities - ALAMar 16, 2022

Earlier from Arovella Therapeutics

  • Suspension from QuotationOct 11, 2023
  • Response to ASX Price QueryAug 30, 2023
  • Quarterly Appendix 4C and Activities ReportJul 24, 2023
  • Completion of oversubscribed Share Purchase Plan (SPP)Jul 10, 2023
  • Share Purchase Plan (SPP) Closing Date ExtendedJun 28, 2023

Later from Arovella Therapeutics

  • Arovella licenses novel solid tumour targeting technologyOct 11, 2023
  • Arovella receives R&D tax credit of $1.94 millionNov 20, 2023
  • Arovella licenses novel CAR-iNKT cell armouring technologyJan 29, 2024
  • Appendix 4D and Half Year ReportFeb 28, 2024
  • Pause in TradingMar 21, 2024
All Arovella Therapeutics news releases↗

Follow Arovella Therapeutics into a list and get an email when it puts out news.

Follow Arovella Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer